A Clear Shift Towards Evidence-Led Equitable Care
1. Moving away from low value interventions
One of the clearest themes of the 2026 update is the firm move away from fertility “add ons” and interventions that have not shown a clear benefit in improving live birth outcomes. NICE explicitly recommends against the routine use of a number of practices that have become relatively widespread in recent years, including endometrial scratch, endometrial receptivity testing (such as ERA and microbiome analysis), immunological treatments (including intralipids, IVIG and steroids), sperm DNA fragmentation testing, PGT A for improving live birth rates, and advanced sperm selection techniques such as IMSI and PICSI.
This signals an important reset: fertility care should be driven by robust evidence and measurable outcomes, rather than hope based or commercialised add ons. The intention is to reduce variation in practice, avoid unnecessary emotional and financial burden for patients, and ensure that treatment decisions are clinically justified.
2. A stronger spotlight on male factor fertility
Another major shift in 2026 is the strengthened focus on male factor fertility. Historically, fertility investigations have often centred on the partner with female reproductive organs. The updated guidance clearly redresses this imbalance.
NICE now places greater emphasis on thorough male assessment, including routine physical examination after repeated abnormal semen analyses, earlier hormonal testing, and clearer use of genetic investigations such as Y chromosome microdeletion testing, CFTR mutation testing, and karyotyping where appropriate. Importantly, the guideline also tightens recommendations around treatments that should not be used in male infertility where evidence is weak.
This represents a step change in acknowledging male fertility as an equal and essential component of reproductive health, with implications not just for conception but for wider long term health.
3. Clearer pathways and fairer access
The 2026 guideline also focuses heavily on standardising pathways and removing ambiguity that has historically led to postcode variation.
Key clarifications include confirming that miscarriage or ectopic pregnancy should not reset eligibility timeframes for fertility assessment or treatment, earlier referral for people aged 36 and over, clearer definitions of what constitutes a full IVF cycle, and more consistent timelines across spontaneous conception, IUI and donor insemination pathways.
These changes are designed to reduce unnecessary delays, improve transparency for patients, and create a more equitable system across regions.
4. A more nuanced approach to IVF
IVF access remains a central element of the guideline, but the approach in 2026 is more data driven and individualised. Ovarian reserve testing (using AMH or AFC) is now formally recognised as part of discussions around IVF suitability and expected outcomes.
The updated guidance strengthens the case for offering up to three full IVF cycles to those under 40, supported by improved cost effectiveness modelling, while allowing consideration of further cycles on a case by case basis. For those aged 40 – 41, one full cycle is recommended, while IVF is not considered cost effective beyond age 42.
Overall, IVF is positioned less as a default entitlement and more as a carefully considered intervention, aligned to realistic outcomes and responsible use of NHS resources.
5. Expanded thinking on fertility preservation
A quieter but significant change in 2026 is the expansion of fertility preservation beyond oncology. NICE now recommends that fertility preservation should be discussed with anyone undergoing medical or surgical treatment likely to impair fertility, not just those with cancer.
This includes clearer guidance on sperm, oocyte, embryo and ovarian tissue cryopreservation, alongside expectations for long term follow up of stored material. This reflects a broader, more preventive approach to reproductive health across the life course.
6. What this means overall
Taken together, the 2026 NICE fertility guideline represents a maturing of fertility care in the UK. The focus has shifted from doing “more” to doing what works, from fragmented practice to consistency, and from female centric pathways to genuinely shared responsibility.
For clinicians, organisations and partners working in fertility and reproductive health, the message is clear: value, evidence and equity are now firmly at the centre of fertility care.
Click to read the full NICE Guidline (NG257): https://www.nice.org.uk/guidance/ng257